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aternal hormonal and metabolic fac-
tors related to the placenta, adipose 
tissue and the growth hormone axis 
are associated with the variation in insulin sensitivity seen 
during normal human pregnancy1. Obesity-mediated fac-
tors potentially may be relevant to the pathophysiologic 
relationship between weight gain and preeclampsia. Re-
cently, low circulating levels of adiponectin and increased 
leptin and C-reactive protein (CRP) have emerged as novel 
diabetic risk factors; although their relevance to gesta-
tional diabetes mellitus (GDM) and subsequent diabetes 
has not been characterized. In the past decade, a grow-
ing body of evidence has identified two pathologic se-
quelae of obesity that may link adiposity to diabetic risk: 
increased serum leptin and low circulating levels of the 
insulin-sensitizing protein adiponectin2,3. 
Adiponectin
Adiponectin, an adipokine produced abundantly by adi-
pocytes, is the most abundant gene (AMP1) product of 
adipose tissue4, and circulates at high concentrations 
in the plasma5. This adipokine consists of three hetero-
geneous species of multimers that can exert differential 
biological effects: a) low-molecular-weight (LMW) trimers, 
b) medium-molecular-weight (MMW) hexamers and c) 
high-molecular weight (HMW) isoform6-8. Unlike other 
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La adiponectina y leptina en la hipertensión inducida por el embarazo, una cuestión de peso 
Niveles bajos circulantes de adiponectina en conjunto con 
niveles altos de leptina han sido identificados como fac-
tores de riesgo noveles para diabetes y preeclampsia. Aun 
en presencia de embarazo normal, mujeres son sobrepeso 
embarazados tienen concentraciones bajas de adiponec-
tina en comparación con aquellas normopeso. Más aún, 
niveles bajos de adiponectina en el primero trimestre es 
un factor de riesgo independiente para el desarrollo de 
diabetes mellitus gestacional (GDM). Concentraciones cir-
culantes de leptina durante el embarazo, se elevan 2 o 3 
veces por encima de lo observado en mujeres no gestan-
tes, y se elevan aún más en preeclampsia. Desafortunada-
mente, no hay existen puntos de referencia reproducibles 
y validados para leptina mensuales en el embarazo. Es ne-
cesario estandarizar (si es necesario) los posibles valores 
de referencia de estas adipokinas como marcadores de 
desarrollo de preeclampsia.
Palabras Claves: adiponectina; diabetes gestacional; lep-
tina; preeclampsia; diabetes tipo 2; peso.
Low circulating levels of adiponectin and increased leptin 
have emerged as novel diabetic and preeclamptic risk 
factors. Even in the presence of a normal pregnancy, 
overweight pregnant women have a lower adiponectin 
concentration than those with a normal weight. More-
over, low concentrations of adiponectin in the first or 
early second trimester is an independent risk factor for 
the development of Gestational Diabetes Mellitus (GDM). 
Circulating leptin concentrations during pregnancy are el-
evated 2 to 3 fold above that observed in nonpregnant 
women, leptin concentrations are further elevated in pre-
eclampsia. Unfortunately until now, there are not repro-
ducible and widely accepted references for adiponectin 
and leptin for every month of pregnancy. So it is necesary 
to standardize the methodologies and propose posible 
values (if useful) of these adipokines as prognosis markers 
to develop preeclampsia.
Keywords: adiponectin; gestational diabetes; leptin; pre-
eclampsia; type 2 diabetes mellitus; weight
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adipokines, adiponectin concentrations are negatively cor-
related with adiposity9, suggesting that adipose tissue ex-
erts a negative feedback on adiponectin production and/
or secretion. Adiponectin is postulated to play a role in 
the modulation of glucose and lipid metabolism in insulin-
sensitive tissues10,11, besides antiinflammatory properties12, 
thus providing a mechanistic molecular basis for the as-
sociation between an excess fat depot and obesity-related 
complication including type 2 diabetes mellitus (2DM). 
Moreover, recent findings indicate that adiponectin has 
antiatherogenic, anti-diabetic and angiogenic properties13. 
Data regarding circulating maternal adiponectin multim-
ers concentrations in human pregnancy are limited14-16. 
Normal pregnancy is associated with alterations in ma-
ternal circulating adiponectin17-19 and with changes in the 
relative distribution of its isoforms20,21. In addition, even 
in the presence of a normal pregnancy, overweight preg-
nant women have a lower adiponectin concentration than 
those with a normal weight22. Moreover, low concentra-
tions of adiponectin in the first or early second trimes-
ter is an independent risk factor for the development of 
GDM. Indeed, maternal adiponectin concentration < 6.4 
µg/ml at 13 weeks of gestation is associated with a 4.6-
fold increased risk to develop GDM later in pregnancy23, 
suggesting a causal relationship between low circulating 
adiponectin and GDM24-26. Collectively, a growing body of 
evidence points to a key role of adiponectin in the patho-
physiology of both 2DM and GDM.
This hormone has been implicated in both the physiologi-
cal adaptation to normal pregnancy and in obstetrical 
complications27. Circulating adiponectin concentrations 
decrease in insulin-resistant states, including 2DM11,28. 
Hypoadiponectinemia in pregnancy predicts postpartum 
insulin resistance, beta-cell dysfunction, and fasting gly-
caemia29. Low adiponectin levels in intra uterine growth 
restriction (IUGR) infants may actually predict the subse-
quent development of visceral fat and insulin resistance30. 
Previous studies have demonstrated that, in pregnancy, 
women with GDM exhibit evidence of sub-clinical inflam-
mation and dysregulation of adipokines, including low 
circulating levels of both adiponectin and its HMW multi-
meric form21,23. In fact, both sub-clinical inflammation and 
hypoadiponectinemia may be chronic defects in this pa-
tient population, as increased CRP and low adiponectin in 
the first trimester have each been shown to independent-
ly predict the subsequent development of GDM later in 
pregnanc23. The significance of the current findings rests 
in the potential implications that a relationship between 
antepartum adiponectin and future 2DM could hold for 
diabetic risk stratification and modification. Specifically, 
it follows from these data that antepartum adiponectin 
concentration may provide a means of stratifying women 
with GDM with respect to their future risk of 2DM. Ideally, 
this information could help to target postpartum surveil-
lance efforts to those women at the highest risk of de-
veloping diabetes. The availability of this predictor at the 
time of diagnosis in pregnancy may be particularly impor-
tant, in light of the well-recognized sub-optimal rates of 
postpartum metabolic follow-up in women with GDM31. 
Secondly, the current data also suggest that chronic hy-
poadiponectinemia could provide a therapeutic target for 
risk modification in this patient population. In this respect, 
it is of interest to note that thiazolidinedione therapy, 
which has been shown to preserve beta-cell function and 
significantly reduce the risk of developing 2DM in women 
with a history of GDM32 is also known to increase adipo-
nectin levels. It thus emerges that a pathophysiologic rela-
tionship between hypoadiponectinemia and diabetic risk 
following GDM could hold important clinical implications.
Leptin
The central source of leptin is the adipose tissue, although 
it can also be produced in other sites, including the pla-
centa33,34, in fact, microarray experiments have demon-
strated a higher expression profile of placental leptin gene 
in preeclamptic women than in normal pregnancies35.
Leptin mainly acts by binding to specific central and pe-
ripheral receptors in the hypothalamus, adipose tissue, liv-
er, and pancreatic beta-cells36. Leptin stimulates a negative 
energy balance by increasing energy expenditure and re-
ducing food intake37. Rodents and humans lacking leptin 
or functional leptin receptors develop severe obesity and 
hyperphagia38. However, endogenous hyperleptinemia 
fails to stimulate body weight loss in obese individuals, 
suggesting that a state of leptin resistance is linked to the 
development of obesity39. 
Leptin receptor is a possible new candidate for the en-
docrine control of human pregnancy40. To maintain the 
increased energy intake in the face of increased adiposity 
and rising leptin levels, pregnant females become resistant 
to the central anorectic actions of leptin. In rats, pregnan-
cy-induced leptin resistance is characterised by elevated 
neuropeptide Y (NPY) and reduced pro-opiomelanocortin 
(POMC) expression in the arcuate nucleus (Arc), reduced 
leptin receptor mRNA levels and suppression of leptin-in-
duced phosphorylated signal transducer and activator of 
transcription-3 protein (STAT-3) in the ventromedial hypo-
thalamic nucleus, as well as a loss of anorectic responses to 
both leptin and alpha-melantocyte-stimulating hormone (a-
MSH). This leptin-resistance may also cause central insulin 
resistance and an altered peripheral glucose homeostasis41. 
Even more, findings from a Chinese group suggest that the 
Lys656Asn polymorphism, a functional variant in the LEPR, 
and high leptin levels are risk factors for preeclampsia42.
Leptin is produced in both maternal and fetal adipose tis-
sues and the placenta43,44, while its receptors are abundant 
in the uterine endometrium, trophoblast, and the fetus45. 
Fetal adipose tissue is an important source of leptin and 
fetal leptin levels are strongly related to birth weight and 
fetal adiposity46-48. The role of leptin in placental function 
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has not been fully elucidated but it is supposed to play a 
role in the regulation of placental amino acid transport by 
activation of the JAK-STAT pathway49. 
A possible leptin’s involvement in pathophysiological ad-
aptations that define the foetal growth potential can be 
supported50, because this adipokine seems to be a criti-
cal factor for overall fetal development42,51. For example, 
maternal first trimester serum leptin demonstrates a sig-
nificant negative association with neonatal weight in pre-
eclamptic pregnancies and to a lesser extent in normoten-
sive pregnancies. 
Furthermore, a strong association between neonatal leptin 
levels, bone mineral content and estimated bone density 
has been confirmed, supporting a role for leptin in the pro-
cess of fetal bone remodelling52. Leptin may play a role in 
the control of substrate utilization and in the maintenance 
and functional characteristics of fat mass before birth, pro-
ducing permanent changes concerning adiposity and body 
composition in adult life.
Circulating leptin concentrations during pregnancy are 
elevated 2 to 3 fold above that observed in nonpregnant 
women, leptin concentrations are further elevated in the 
pregnancy complication preeclampsia and are lower in 
pregnancies complicated by IUGR53,54. However, clinical and 
experimental trials have not yet clarified the definite role 
of leptin in the pathophysiologic mechanisms of high-risk 
pregnancies55,56. Previous studies have demonstrated that 
plasma leptin concentrations are increased significantly 
during the third trimester of preeclamptic pregnancies in 
contrast to normal pregnancies57,58. Other studies have doc-
umented that plasma leptin levels are elevated even before 
preeclampsia had become clinically evident59-61. Amongst 
the groups involved in the study of leptin and preeclampsia 
our team has showed that a value above 40 ng/ml in the 
third trimester of pregnancy seems to be a good predictor 
for preeclampsia62. However, the exact mechanism underly-
ing the increased plasma leptin levels in preeclampsia and 
the functional role of leptin in the development of hyper-
tension need to be further clarified63. How the knowledge 
that leptin is associated to hypertension could be applied in 
clinical practice is still a matter of debate.
Impaired Glucose Tolerance (IGT) during pregnancy is 
associated with leptin gene DNA methylation adapta-
tions with potential functional impacts. These epigenetic 
changes provide novel mechanisms that could contribute 
to explaining the detrimental health effects associated 
with fetal programming, such as long-term increased risk 
of developing obesity and 2DM64. 
Until now, there are several papers relating to leptin and 
adiponectin in pregnancy but we have found heterege-
nous results (Table 1). So it is necesary to standardize the 
methodologies and propose posibles values (if useful) as 
prognosis markers to develop preeclampsia.
Summary
Maternal adipokines are related to several diseases. Be-
ing more specific, adiponectin has antiatherogenic, anti-
diabetic and angiogenic properties but in pregnancy over-
weight women have a lower adiponectin concentration 
than those with a normal weight. In relation to leptin, 
its concentrations during pregnancy are elevated 2 to 3 
fold above the values observed in nonpregnant women, 
and are further elevated in preeclampsia. Our group has 
reported that in Mexican morbid obese women, a value 
higher than 40 ng/ml in the second trimester, is highly 
predictive of preeclampsia. To our best knowledge there 
isn’t any drug targeting at leptin receptor to explore new 
antihypertensive options. 
 Table 1. Comparative values reported for leptin and adiponectin in pregnancy*
Month
3 4 7 8 9
N
or
m
al
IG
T
O
ve
rw
ei
gh
t
N
or
m
al
IG
T
G
D
M
N
or
m
al
IG
T
G
D
M
N
or
m
al
O
be
si
ty
Se
ve
re
 
pr
ee
cl
am
ps
ia
N
or
m
al
IG
T
G
D
M
O
ve
rw
ei
gh
t
O
be
si
ty
M
ild
 
pr
ee
cl
am
ps
ia
Se
ve
re
 
pr
ee
cl
am
ps
ia
Adiponectin (µg/ml)
Retnakaran R29 8 7 7
Mazaki-Tovi S18 6.019 3.022 5.207
Nien JK27;65 8.48 6.946 9.632
Nakatsukasa H66 13 30
Gao XL67 9.18 6.88 5.06 5.7 4.5 3
Kyriakakou M68 11.8
Leptin (ng/ml)
Retnakaran R29 32.9 35.7 35.8
Bouchard L64 28.9 25.8 44.1 25.7
Nakatsukasa H66 20 21
Sucak A63 16.3 30.6 31.7
Kim KH69 9.87 17.8 15.73 20.93
Gao XL67 4.89 9.61 12.79 8.88 15.11 22.64
Kyriakakou M68 20.4
IGT: impaired glucose test, GDM: gestational diabetes mellitus.
* If necesary,values have been transformed into the same units, µg/ml for adiponectin and ng/ml for leptin.
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